Company intelligence / Profile preview
StemCells, Inc.
Newark, California, United Statesstemcellsinc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells in a Phase I clinical trial for Pelizaeus-Merzbacher disease. They were also conducting Phase I/II clinical trials in chronic spinal cord injury and dry age-related macular degeneration, with positive interim data reported for the first three patients in the spinal cord injury trial.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Cell-based therapeutics (human neural stem cells)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on StemCells, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StemCells, Inc..